Results 131 to 140 of about 81,932 (265)

Identification and characterization of lncRNA-stemness-immune regulatory patterns. [PDF]

Brief Bioinform
Qian Z, Yin J, Zhang C, Wang G, Wang C, Li Y, Zhao Y.   +6 more
europepmc   +1 more source

Stem Cells [PDF]

Neuro-Oncology, 2010
L. Cheng, Z. Huang, W. Zhou, Q. Wu, J. Rich, S. Bao, P. Baxter, H. Mao, X. Zhao, Z. Liu, Y. Huang, H. Voicu, S. Gurusiddappa, J. M. Su, L. Perlaky, R. Dauser, H.-c. E. Leung, K. M. Muraszko, J. A. Heth, X. Fan, C. C. Lau, T.-K. Man, M. Chintagumpala, X.-N. Li, P. Clark, M. Zorniak, Y. Cho, X. Zhang, D. Walden, E. Shusta, J. Kuo, S. Sengupta, S. Goel-Bhattacharya, S. Kulkarni, B. Cochran, C. Cusulin, A. Luchman, S. Weiss, M. Wu, N. Fernandez, S. Agnihotri, R. Diaz, J. Rutka, M. Bredel, J. Karamchandani, S. Das, B. Day, B. Stringer, F. Al-Ejeh, M. Ting, J. Wilson, K. Ensbey, P. Jamieson, Z. Bruce, Y. C. Lim, C. Offenhauser, S. Charmsaz, L. Cooper, J. Ellacott, A. Harding, J. Lickliter, P. Inglis, B. Reynolds, D. Walker, M. Lackmann, A. Boyd, A. Berezovsky, L. Poisson, L. Hasselbach, S. Irtenkauf, A. Transou, T. Mikkelsen, A. C. deCarvalho, D. Emlet, C. Del Vecchio, P. Gupta, G. Li, S. Skirboll, A. Wong, J. Figueroa, T. Shahar, A. Hossain, F. Lang, S. Fouse, J. Nakamura, C. D. James, S. Chang, J. Costello, J. M. Frerich, S. Rahimpour, Z. Zhuang, J. D. Heiss, A. Golebiewska, D. Stieber, L. Evers, E. Lenkiewicz, N. H. C. Brons, N. Nicot, A. Oudin, S. Bougnaud, F. Hertel, R. Bjerkvig, M. Barrett, L. Vallar, S. P. Niclou, X. Hao, J. Rahn, E. Ujack, X. Lun, G. Cairncross, S. Weiss, D. Senger, S. Robbins, J. Harness, R. Lerner, Y. Ihara, R. Santos, J. D. L. Torre, A. Lu, T. Ozawa, T. Nicolaides, D. James, C. Petritsch, D. Higgins, M. Schroeder, B. Ball, B. Milligan, F. Meyer, J. Sarkaria, J. Henley, W. Flavahan, Q. Wu, M. Hitomi, N. Rahim, Y. Kim, A. Sloan, R. Weil, I. Nakano, J. Sarkaria, B. Stringer, M. Li, J. Lathia, J. Rich, A. Hjelmeland, M. Kaluzova, S. Platt, M. Kent, A. Bouras, R. Machaidze, C. Hadjipanayis, S.-G. Kang, S.-H. Kim, Y.-M. Huh, E.-H. Kim, E.-K. Park, J. H. Chang, S. H. Kim, Y. K. Hong, D. S. Kim, S.-J. Lee, E. H. Kim, S. G. Kang, M. Hitomi, L. Deleyrolle, M. Sinyuk, M. Li, W. Goan, B. Otvos, M. Rohaus, M. Oli, V. Vedam-Mai, D. Schonberg, Q. Wu, J. Rich, B. Reynolds, J. Lathia, S.-T. Lee, K. Chu, S.-H. Kim, S. K. Lee, M. Kim, J.-K. Roh, R. Lerner, A. Griveau, Y. Ihara, B. Reichholf, M. McMahon, D. Rowitch, D. James, C. Petritsch, R. Nitta, S. Mitra, M. Agarwal, T. Bui, G. Li, J. Lin, C. Adamson, J. Martinez-Quintanilla, S.-H. Choi, D. Bhere, A. Shavkunov, R. Spelat   +201 more
openaire   +3 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide. [PDF]

BJC Rep
Rancati S, Campolungo M, Duarte Dalmolin G, Lau P, Furia F, Coppe A, Landuzzi F, Vecchi M, Cavalli A, Gustincich S, Tirelli N.   +10 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

From State, Pathway, to Niche: The Ternary Network of Breast Cancer Stem-like Cells Driving Tumor Progression and Combination Therapy Prospects. [PDF]

Biomolecules
Man S, Zhang L, Chen B.
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Integrated single-cell and bulk transcriptomic analyses reveal a stem-like epithelial subpopulation in adenocarcinoma of the esophagogastric junction and identify VASN as a novel regulator of tumor stemness. [PDF]

Front Immunol
Zheng H, Wang S, Liu H, Wang J, Hu B.
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

The resilient subset: cancer stem cells at the core of immunotherapy resistance. [PDF]

Immunother Adv
Gajón JA, Esperante D, Ko N, Jimenez-Miranda A, Muñoz-Cruz S, Fuentes-Panana E, Bonifaz LC.   +6 more
europepmc   +1 more source